Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 25, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Annual Investment Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the share price of GBP 12.56 per share, which was the price used for the re-investment of dividends paid on October 11, 2007.
Material Changes
The document reports an increase in share interests for specific individuals following the re-investment of dividends. There is no data provided regarding material changes in financial performance compared to prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly details the notification of share transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Dividend re-investment occurred at a price of GBP 12.56 per share.
- Dividends were originally paid to shareholders on October 11, 2007.
- Specific share increases were recorded for Dr M M Slaoui (206 shares), Mr R M Bondy (265 shares), Mr M M Dunoyer (99 shares), Mr D Learmouth (17 shares), Dr D Pulman (152 shares), and Mr A P Witty (92 shares).
- The report was signed by Victoria Whyte as the Authorised Signatory on October 25, 2007.